Divis Laboratories Stock Analysis: Deven Choksey Maintains 'Accumulate' Rating, Sets INR 6,795 Target on Strong Custom Synthesis Performance

Overview

Analyst Deven Choksey has released a report on Divis Laboratories, noting a consolidated revenue increase of 16.1% year-on-year to INR 27,150 million, slightly exceeding estimates. This growth was primarily driven by the Custom Synthesis segment, which performed better than expected, while the Generic API business faced ongoing pricing pressures. The outlook remains positive, with a target price of INR 6,795 set for September 2027. Choksey reiterates an "ACCUMULATE" rating for the stock.